The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
Subscribe To Our Newsletter & Stay Updated
